Cargando…

Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non‐small cell lung cancer after stereotactic body radiation therapy

INTRODUCTION: After treatment with stereotactic body radiation therapy (SBRT), local recurrence of non‐small cell cancer (NSCLC) can be difficult to differentiate from radiation‐induced changes. Maximum standardized uptake value (SUVmax), measured with 18‐F‐Fluorodeoxyglucose positron emission tomog...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Daren, Gill, Suki, Loh, Nelson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571834/
https://www.ncbi.nlm.nih.gov/pubmed/32846054
http://dx.doi.org/10.1002/cam4.3302
_version_ 1783597228720390144
author Tan, Daren
Gill, Suki
Loh, Nelson
author_facet Tan, Daren
Gill, Suki
Loh, Nelson
author_sort Tan, Daren
collection PubMed
description INTRODUCTION: After treatment with stereotactic body radiation therapy (SBRT), local recurrence of non‐small cell cancer (NSCLC) can be difficult to differentiate from radiation‐induced changes. Maximum standardized uptake value (SUVmax), measured with 18‐F‐Fluorodeoxyglucose positron emission tomography (FDG‐PET), can have false positives due to acute radiation inflammation. The primary study objective was to determine the utility of SUVmax > 5 to identify local recurrence later than 9 months after SBRT. METHOD: A retrospective review was performed of FDG‐PET scans for suspicious CT findings after SBRT treatment of stage 1 NSCLC. SUVmax was measured including surrounding opacification. Outcome measures were local recurrence, progression free survival, and overall survival. Receiver operator curve analysis, sensitivity, specificity, and Kaplan‐Meier analysis were performed. RESULTS: Of 118 patients treated, 42 patients had eligible FDG‐PET scans. They received SBRT (48‐60Gy in 3‐8 fractions) for 49 NSCLC and had 101 follow‐up PET scans. The median time to first PET scan was 9.3 months, and the median follow‐up period was 22.4 months. Local recurrence was diagnosed in 12 patients, at a median of 16 months. Due to selection bias, the included patients had poorer outcomes than the entire cohort, with progression free survival (PFS) at 1, 2, and 3 years of 82.7%, 57.8%, and 45.8%; and overall survival of 97.9%, 79.9%, and 59.1%, respectively. Thirty FDG‐PET scans were performed within 9 months, of which 17% were false positives. A total of 71 FDG‐PET scans were performed beyond 9 months, and the median SUVmax was significantly higher for patients with local recurrence (7.48 vs. 2.14, P < .0001). SUVmax > 5 has a sensitivity of 91% (95% CI 62%‐99.8%) and 100% (89.1%‐100%). CONCLUSION: For local recurrence of NSCLC, SUVmax > 5 on FDG‐PET scan has good sensitivity and specificity after 6 months, but is highest beyond 9 months after SBRT.
format Online
Article
Text
id pubmed-7571834
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75718342020-10-23 Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non‐small cell lung cancer after stereotactic body radiation therapy Tan, Daren Gill, Suki Loh, Nelson Cancer Med Clinical Cancer Research INTRODUCTION: After treatment with stereotactic body radiation therapy (SBRT), local recurrence of non‐small cell cancer (NSCLC) can be difficult to differentiate from radiation‐induced changes. Maximum standardized uptake value (SUVmax), measured with 18‐F‐Fluorodeoxyglucose positron emission tomography (FDG‐PET), can have false positives due to acute radiation inflammation. The primary study objective was to determine the utility of SUVmax > 5 to identify local recurrence later than 9 months after SBRT. METHOD: A retrospective review was performed of FDG‐PET scans for suspicious CT findings after SBRT treatment of stage 1 NSCLC. SUVmax was measured including surrounding opacification. Outcome measures were local recurrence, progression free survival, and overall survival. Receiver operator curve analysis, sensitivity, specificity, and Kaplan‐Meier analysis were performed. RESULTS: Of 118 patients treated, 42 patients had eligible FDG‐PET scans. They received SBRT (48‐60Gy in 3‐8 fractions) for 49 NSCLC and had 101 follow‐up PET scans. The median time to first PET scan was 9.3 months, and the median follow‐up period was 22.4 months. Local recurrence was diagnosed in 12 patients, at a median of 16 months. Due to selection bias, the included patients had poorer outcomes than the entire cohort, with progression free survival (PFS) at 1, 2, and 3 years of 82.7%, 57.8%, and 45.8%; and overall survival of 97.9%, 79.9%, and 59.1%, respectively. Thirty FDG‐PET scans were performed within 9 months, of which 17% were false positives. A total of 71 FDG‐PET scans were performed beyond 9 months, and the median SUVmax was significantly higher for patients with local recurrence (7.48 vs. 2.14, P < .0001). SUVmax > 5 has a sensitivity of 91% (95% CI 62%‐99.8%) and 100% (89.1%‐100%). CONCLUSION: For local recurrence of NSCLC, SUVmax > 5 on FDG‐PET scan has good sensitivity and specificity after 6 months, but is highest beyond 9 months after SBRT. John Wiley and Sons Inc. 2020-08-26 /pmc/articles/PMC7571834/ /pubmed/32846054 http://dx.doi.org/10.1002/cam4.3302 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Tan, Daren
Gill, Suki
Loh, Nelson
Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non‐small cell lung cancer after stereotactic body radiation therapy
title Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non‐small cell lung cancer after stereotactic body radiation therapy
title_full Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non‐small cell lung cancer after stereotactic body radiation therapy
title_fullStr Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non‐small cell lung cancer after stereotactic body radiation therapy
title_full_unstemmed Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non‐small cell lung cancer after stereotactic body radiation therapy
title_short Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non‐small cell lung cancer after stereotactic body radiation therapy
title_sort timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non‐small cell lung cancer after stereotactic body radiation therapy
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571834/
https://www.ncbi.nlm.nih.gov/pubmed/32846054
http://dx.doi.org/10.1002/cam4.3302
work_keys_str_mv AT tandaren timingoffluorodeoxyglucosepositronemissiontomographymaximumstandardizeduptakevaluefordiagnosisoflocalrecurrenceofnonsmallcelllungcancerafterstereotacticbodyradiationtherapy
AT gillsuki timingoffluorodeoxyglucosepositronemissiontomographymaximumstandardizeduptakevaluefordiagnosisoflocalrecurrenceofnonsmallcelllungcancerafterstereotacticbodyradiationtherapy
AT lohnelson timingoffluorodeoxyglucosepositronemissiontomographymaximumstandardizeduptakevaluefordiagnosisoflocalrecurrenceofnonsmallcelllungcancerafterstereotacticbodyradiationtherapy